Overcoming challenges to COVID-19 clinical trials: Optimized solutions to drive therapeutic and vaccine development success.

Summary of webinar:
The COVID-19 pandemic has seen an unparalleled global mobilization of resources and expertise. There are currently many clinical trials in the COVID-19 space as the development of vaccines and therapeutics progresses. These trials present with unique challenges that require innovative solutions and insights.
Join us as we examine these challenges and discuss solutions to each.


During the course of the webinar we will be discussing:
  • The challenges and benefits of serological data and their impact on study progression.
  • The unique challenges of paediatric trials.
  • Issues in sample collection procedures across various sample types and patient demographics.
  • Serological, genetic and cellular insights in SARS-CoV-2 infections and vaccine efficacy.


Matti Kimberg
Matti is a molecular geneticist (University of Stellenbosch) and immunologist (University of Cape Town) and has more than 10 years’ experience in regulated bioanalysis and clinical biomarkers.As CSO, his primary focus is to ensure that the execution of all work performed at Synexa is scientifically driven by the objective of generating data that is informative towards answering the specific questions being asked in the context of each study. He has a deep understanding of the principals of the regulatory framework supporting bioanalysis and applying the guidelines provided by regulators to novel analytical technologies and therapeutic modalities.
Matti is passionate about using world class science and innovation to transform the way novel therapeutics are developed, to bring them to market faster, cheaper and safer.
Nicholas Woudberg, PhD
Nick is a scientist and scientific consultant at Synexa. Most of his time is spent validating, developing and applying novel immunological methods to our client’s unique specifications. During the initial outbreak of COVID-19, Nick was involved in the establishment of Synexa’s in-house serological assay. Following the validation of this method, Nick was responsible for preparing the published manuscript on the data generated. He is passionate about continuing to apply his knowledge to new and exciting research areas. Nick continues his work in thelab but is also transitioning into a consulting role alongside Chief Medical Officer, Dr Justin Devine, where he will engage with potential clients, assisting in the design of novel biomarker strategies and providing solutions for research questions and methodology.
Andreia Soares, PhD
Andreia is a cellular immunologist with extensive experience in advanced immunological techniques, such as multiparameter flow cytometry. She brings with her a unique perspective on biomarker discovery with her background in infectious diseases and clinical immunology.
She completed her PhD in Clinical Science and Immunology at the University of Cape Town, which focused on Bacille Calmette Guérin (BCG)-specific T cell mediated immunity following vaccination of newborns. The predominant focus ofher post-doctoral work was on new vaccination strategies against HIV. Andreia has several international peer-reviewed publications related to HIV and TB and her area of interest is focused on attaining a better understanding of cellular immunity related to infectious diseases and vaccine induced immune responses. Andreia is based at our London laboratory and leads our work globally in flow cytometry and cell-based assay innovation and application.
Florian Lapierre, PhD
General Manager - Microsampling Business Unit @Trajan Scientific and Medical
Florian is a scientist with background in micro and nanotechnology for medical applications. As General Manager of the Trajan Microsampling Business Unit, his mission is to provide customers disruptive healthcare solutions that address unmet needs that challenges our communities. He is the initiator of the hemaPEN platform technology, and since 2018 is leading the implementation of such patient-centric technologies for providing world class clinical services in therapeutic drug monitoring, workplace testing, surveillance programs, and neglected tropical disease eradication programs. He engages with strategic international partners to implement these solutions and assess their analytical and clinical performance. Florian is a technology enthusiast driven to empower people with pioneered healthcare solutions that will ultimately benefit human wellbeing.
Session 1:
Tuesday, July 27, 2021 – 4:00 PM
(9:00 AM ET; 3:00 PM CET)
Session 2:
Tuesday, July 27, 2021 – 7:00 PM
(12:00 PM ET; 09:00 AM PT)
Webinars will be available for on-demand viewing after the event.
Follow our LinkedIn page to stay up to date and for more events like this in the future.